<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Dynamic Topic Modeling of Kratom Use and Experiences: Insights on 13 years of Reddit Discussions</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Seraphina</forename><surname>Fong</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Psychology and Cognitive Science</orgName>
								<orgName type="institution">University of Trento</orgName>
								<address>
									<settlement>Rovereto</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alessandro</forename><surname>Carollo</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Psychology and Cognitive Science</orgName>
								<orgName type="institution">University of Trento</orgName>
								<address>
									<settlement>Rovereto</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elisabeth</forename><surname>Prevete</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Psychiatry and Clinical Psychopharmacology University Unit</orgName>
								<orgName type="institution">ASL Latina Hospital</orgName>
								<address>
									<settlement>Terracina</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ornella</forename><surname>Corazza</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Psychology and Cognitive Science</orgName>
								<orgName type="institution">University of Trento</orgName>
								<address>
									<settlement>Rovereto</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">University of Hertfordshire</orgName>
								<address>
									<settlement>Hatfield</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Gianluca</forename><surname>Esposito</surname></persName>
							<email>gianluca.esposito@unitn.it</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Psychology and Cognitive Science</orgName>
								<orgName type="institution">University of Trento</orgName>
								<address>
									<settlement>Rovereto</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Dynamic Topic Modeling of Kratom Use and Experiences: Insights on 13 years of Reddit Discussions</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">698F82EA5CBB9197713B627D3FCB25DD</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2025-10-19T16:58+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Conceptualization SF, AC, OC, GE</term>
					<term>methodology, investigation, software SF</term>
					<term>formal analysis SF, AC</term>
					<term>writing -original draft preparation SF, EP</term>
					<term>review and editing SF, AC, EP, OC, and GE</term>
					<term>supervision GE Kratom, topic modeling, natural language processing, reddit, BERTopic, addiction science</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Data availability statement: The raw data used for the present study was obtained from a public repository in light of Reddit's application programming interface (API) privacy policy changes in June 2023. The repository is a large public dataset containing posts and comments from the top 40,000 subreddits obtained and stored publicly by an approved Reddit moderator. It was accessed via the following link: https://www.reddit.com/r/pushshift/comments/1akrhg3/separate_dump_files_for_the_top_40 k_subreddits/.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Mitragyna speciosa (Rubiaceae family) is a plant from the Southeastern regions of the world, commonly diffused in Thailand, Malaysia, and Indonesia. It can also be found in Africa and Papua New Guinea, among other countries <ref type="bibr" target="#b24">(Grundmann et al., 2023a;</ref><ref type="bibr" target="#b42">Kruegel &amp; Grundmann, 2018;</ref><ref type="bibr">Singh et al., 2017;</ref><ref type="bibr" target="#b88">Swogger et al., 2022)</ref>. Commonly known as kratom, the plant contains several alkaloids and has a complex profile of action, with stimulant effects for doses less than 5g, and sedative action for higher doses (more than 5g) <ref type="bibr">(Cinosi et al., 2015;</ref><ref type="bibr" target="#b24">Grundmann et al., 2023a;</ref><ref type="bibr" target="#b88">Swogger et al., 2022)</ref>. Kratom leaves have been used in traditional medicine for self-treating several common health issues, such as fever or cough, to alleviate opioid withdrawal and pain, among other applications <ref type="bibr" target="#b3">(Brown et al., 2017;</ref><ref type="bibr" target="#b24">Grundmann et al., 2023a;</ref><ref type="bibr" target="#b46">McCurdy et al., 2024;</ref><ref type="bibr">Singh et al., 2017)</ref>, and also among poly-drug users in the native countries <ref type="bibr" target="#b17">(Govarthnapany et al., 2025)</ref>.</p><p>Kratom products (e.g., capsules, powder, others) are derived from the leaves of the plant and have become widely available in the West since 2006, especially in the United States (US) <ref type="bibr" target="#b46">(McCurdy et al., 2024;</ref><ref type="bibr">Smith et al., 2022a;</ref><ref type="bibr" target="#b81">Smith et al., 2023)</ref>, and are reportedly composed by different mitragynine and other alkaloids <ref type="bibr" target="#b33">(Hill et al., 2025;</ref><ref type="bibr">White et al., 2025)</ref>.</p><p>Such products are commonly advertised and sold with different names, generally including a reference to the color and origin of the strains <ref type="bibr" target="#b37">(Huisman et al., 2023)</ref>. However, since there are no clear regulations around selling and manufacturing of such products in Western countries, they might therefore be contaminated with other compounds and potentially result in adverse events <ref type="bibr">(Cinosi et al., 2015;</ref><ref type="bibr" target="#b32">Henningfield et al., 2024;</ref><ref type="bibr" target="#b33">Hill et al., 2025;</ref><ref type="bibr" target="#b52">Papsun et al., 2023;</ref><ref type="bibr" target="#b95">Vadiei et al., 2025)</ref>. Data from surveys have shown that kratom has been used for the self-treatment of pain, mental health related issues (e.g., anxiety, depression), dependence or withdrawal associated with stimulant and/or sedative substances (e.g., alcohol or opioids) <ref type="bibr" target="#b46">(McCurdy et al., 2024;</ref><ref type="bibr" target="#b49">Mun et al., 2025;</ref><ref type="bibr" target="#b81">Smith et al., 2023;</ref><ref type="bibr" target="#b88">Swogger et al., 2022)</ref>, and for lowering metabolic risk factors <ref type="bibr" target="#b64">(Rayanakorn et al., 2025)</ref>. Such self-reported evidence has also been confirmed by (pre)clinical data <ref type="bibr" target="#b48">(MÃ¼ller et al., 2024;</ref><ref type="bibr" target="#b59">Prevete et al., 2023b;</ref><ref type="bibr" target="#b98">Vicknasingam et al., 2020)</ref>. Kratom has also been used to boost energy and to be taken recreationally in combination with other substances <ref type="bibr" target="#b46">(McCurdy et al., 2024;</ref><ref type="bibr" target="#b60">Prevete et al., 2021;</ref><ref type="bibr" target="#b89">Swogger et al., 2015)</ref>. However, while facing a lack of large control clinical trials, concerns about the safety and the risks of unsupervised kratom intake remain high. Some findings suggest that kratom is particularly used among people with substance use disorder, especially opioid use disorder <ref type="bibr" target="#b18">(Green et al., 2024)</ref>. Evidence has also suggested that kratom has some addictive potential especially when used at high doses for a long time, with the risk of developing a typical withdrawal syndrome, sometimes defined as kratom use disorder <ref type="bibr" target="#b14">(Falise et al., 2023;</ref><ref type="bibr" target="#b34">Hill et al., 2023;</ref><ref type="bibr" target="#b66">Rogers et al., 2024b)</ref>. For instance, a high number of toxicities (e.g., neurological, liver and renal, cardiological issues, among others; <ref type="bibr" target="#b0">Alsarraf et al., 2019;</ref><ref type="bibr" target="#b38">Jain &amp; Lloyd, 2025;</ref><ref type="bibr" target="#b45">Leong Bin Abdullah et al., 2021;</ref><ref type="bibr" target="#b68">Schimmel &amp; Dart, 2020)</ref> including fatalities <ref type="bibr" target="#b8">(Corkery et al., 2019;</ref><ref type="bibr" target="#b41">Kerrigan &amp; Basiliere, 2022;</ref><ref type="bibr" target="#b22">Grundmann et al., 2024a;</ref><ref type="bibr" target="#b94">Torrico et al., 2024)</ref>, has been reported among kratom users. These have been highlighted in several case reports from the West, especially when kratom products are consumed with other substances (e.g., opioids) or contain contaminants (e.g., propylhexedrine and phenylethylamine) <ref type="bibr" target="#b8">(Corkery et al., 2019;</ref><ref type="bibr" target="#b23">Grundmann et al., 2024b;</ref><ref type="bibr" target="#b35">Holler et al., 2011;</ref><ref type="bibr" target="#b50">Nacca et al., 2020;</ref><ref type="bibr" target="#b94">Torrico et al., 2024)</ref>. Higher concentrations of alkaloids compared to traditional products and drug-drug interactions are often considered responsible for such toxicities, while small doses are thought to pose fewer risks <ref type="bibr" target="#b11">(Dhoble et al., 2025;</ref><ref type="bibr" target="#b23">Grundmann et al., 2024b</ref><ref type="bibr" target="#b25">Grundmann et al., , 2023b;;</ref><ref type="bibr" target="#b40">Kamble et al., 2020;</ref><ref type="bibr" target="#b90">Tanna et al., 2023)</ref>.</p><p>In this context, users' claims have been of paramount importance to enrich knowledge on kratom use. Studies have increasingly considered online reports and social media analyses to gain a better, naturalistic understanding of the phenomenon <ref type="bibr" target="#b60">(Prevete et al., 2021;</ref><ref type="bibr" target="#b85">Smith et al., 2022b;</ref><ref type="bibr" target="#b86">Smith et al., 2021;</ref><ref type="bibr" target="#b89">Swogger et al., 2015;</ref><ref type="bibr" target="#b93">Tobacyk et al., 2022)</ref>. Evidence emerged from investigations carried out on Bluelight, Twitter, and Reddit showed that the main discussions were related to quitting kratom and reducing the kratom dose because of the personal perception of dependence. Concerns about quality issues were also reported <ref type="bibr" target="#b26">(Grundmann et al., 2022)</ref>. In another study, kratom-related discussions were collected from 42 subreddits in 2019-2020. Both beneficial and adverse effects were described by users, highlighting the complex profile of kratom use <ref type="bibr" target="#b86">(Smith et al., 2021)</ref>. Similarly and more recently, <ref type="bibr" target="#b65">Rogers et al. (2024a)</ref>'s analysis of Reddit data from 2020-2022 revealed mixed experiences when using kratom, with users citing benefits like pain relief and symptom management accompanied by alcohol or opioid use. However, users also expressed concerns about addiction and dependence, inconsistent product quality from vendors, and the desire to quit usage of kratom.</p><p>Although previous studies have investigated topics of discussion related to kratom on various social media platforms <ref type="bibr" target="#b26">(Grundmann et al., 2022;</ref><ref type="bibr" target="#b86">Smith et al., 2021;</ref><ref type="bibr" target="#b65">Rogers et al., 2024a;</ref><ref type="bibr" target="#b100">Wahbeh et al., 2024)</ref>, the emerged evidence was based on manual labeling of topics and, as a consequence, on relatively small sets of posts related to kratom, or analyses conducted through classical topic-modeling techniques. For instance, <ref type="bibr" target="#b26">Grundmann et al. (2022)</ref> analyzed 379 posts sourced from Bluelight, Reddit, and Twitter, while <ref type="bibr" target="#b65">Rogers et al. (2024a)</ref> analyzed 370 Reddit posts. <ref type="bibr" target="#b100">Wahbeh et al. (2024)</ref> applied Latent Dirichlet Allocation (LDA), a classical probabilistic topic-modeling approach, combined with qualitative interpretation and visualization to characterize kratom's benefits and adverse effects.</p><p>However, their analysis was constrained by the lower semantic resolution and scalability of traditional LDA.</p><p>Topic modeling utilizes statistical modeling to extract patterns within a large corpus of unstructured text data in order to derive topics <ref type="bibr" target="#b12">(Egger &amp; Yu, 2022)</ref>. Building on this, the present work aims to extend the insights of the aforementioned works through a more recently developed algorithm called BERTopic <ref type="bibr" target="#b19">(Grootendorst, 2022)</ref>. BERTopic enables the efficient extraction of highly relevant topics without the need of extensive human labeling and classification. Unlike LDA, BERTopic is also able to capture nuanced semantics and automatically produces interpretable topic representations using class-based TF-IDF <ref type="bibr" target="#b2">(Blei &amp; Lafferty, 2006</ref><ref type="bibr" target="#b19">, Grootendorst, 2022)</ref>. These features enable the discovery of prominent discussion themes in large-scale, unstructured social media text. In this way, we aim to identify and extract topics of discussion within a larger-scale dataset of 188,139 kratom-related posts on Reddit from the years 2010 to 2023. Moreover, BERTopic allows for dynamic topic modeling, which provides an insight into how discussions about topics in the corpus evolved over time <ref type="bibr" target="#b2">(Blei &amp; Lafferty, 2006)</ref>. This approach has previously proven useful in characterizing the online discourse about substance use in social media platforms as well as in other domains of clinical psychology <ref type="bibr">(Fong et al., 2025</ref><ref type="bibr" target="#b17">(Fong et al., , 2024))</ref>. Overall, the present work aims to further enhance the current knowledge in the field by analyzing a larger dataset which will enable a comprehensive understanding of the experiences and motivations behind kratom usage as shared by users on social media platforms.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">Method</head><p>This study was approved by the University of Trento Ethical Committee (2024-40 ESA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">Data collection</head><p>The current study is based on data collected from Reddit. Reddit is a community-driven online social news platform where registered users can create or join over 100,000 active online subcommunities to discuss their specific interests (Reddit Homepage, 2024). These subcommunities are referred to as "subreddits" and allow users to share and discuss various topics relevant to the subreddit subject <ref type="bibr" target="#b55">(Pont-Fernandez et al., 2023;</ref><ref type="bibr" target="#b86">Smith et al., 2021)</ref>. For example, the subreddit called "r/addiction" (where "r/" indicates a subreddit) provides a space for individuals to engage in addiction-related discourse.</p><p>Reddit has previously provided valuable insight relevant to the domain of substance use and health sciences (e.g., <ref type="bibr">Fong et al., 2025</ref><ref type="bibr" target="#b17">Fong et al., , 2024))</ref>. For instance, previous studies have examined data from Reddit to gain insight into individuals' behaviors or beliefs behind substance use (e.g., <ref type="bibr" target="#b17">Fong et al., 2024;</ref><ref type="bibr" target="#b55">Pont-Fernandez et al., 2023)</ref> or to check the consistency between survey findings and Reddit posts to understand kratom use patterns <ref type="bibr" target="#b86">(Smith et al., 2021)</ref>.</p><p>Reddit was chosen as the main source for the current study for two main reasons. The first is that users are not restricted to a 280 character limit (as enforced on Twitter) when writing a post or comment. This enables users to potentially provide more in-depth opinions or engage in more nuanced discussions on various topics. The second reason is that Reddit as a platform allows for user anonymity. Therefore, Reddit is a fairly abundant ecological source of human opinions, attitudes, and experiences <ref type="bibr" target="#b101">(Wanchoo et al., 2023)</ref>.</p><p>Previous work (e.g., <ref type="bibr" target="#b101">Wanchoo et al., 2023</ref><ref type="bibr">, Yao et al., 2023)</ref>  A preliminary analysis showed that including all posts from the three general subreddits (r/addiction, r/chronicpain, and r/opiatesrecovery) introduced a lot of noise into the extracted topics (e.g., topics related to sex addiction, marijuana, nicotine; see Figure <ref type="figure" target="#fig_3">S1</ref> in the Supplementary Materials). Therefore, the data from r/addiction, r/chronicpain, and r/opiatesrecovery were filtered to only include posts containing the word 'kratom'.</p><p>Additionally, we conducted a robustness analysis and observed that the inclusion of general subreddits does not significantly bias the results toward specific topics (see Figure <ref type="figure" target="#fig_5">S2</ref> in the Supplementary Materials). Prior to further preprocessing, the dataset contained 340,430 posts from the 15 aforementioned subreddits.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Data preprocessing</head><p>A number of preprocessing steps were conducted to reduce non-textual noise content in the dataset of posts to ensure that the BERTopic model would generate meaningful and interpretable topics <ref type="bibr" target="#b44">(Kumi et al., 2024)</ref>.</p><p>1) Empty posts (null or containing empty strings), emojis, and those indicated as</p><p>[removed] or [deleted] were removed to ensure that only posts with actual content are analyzed <ref type="bibr" target="#b44">(Kumi et al., 2024)</ref>.</p><p>2) Each post's title and body text were merged to ensure a comprehensive analysis of the post to leverage all available textual content. This is because Reddit users often use the title to summarize their thoughts while elaborating in the body text, or, in other cases, the body may only contain pictures or brief follow-ups, while the title will format as indicated by Reddit) were also deleted as they do not provide textual data for topic modeling.</p><p>3) Dates of post creation were converted from unix timestamps to Coordinated Universal Time (UTC) for dynamic topic modeling (see Section 2.3.1 for more details).</p><p>4) All remaining posts were converted to lowercase <ref type="bibr">(Yao et al., 2023)</ref>.</p><p>No further preprocessing (e.g., tokenization, lemmatization, or removing stop words)</p><p>was performed to retain each posts' original structure. In this way, the transformer-based topic models can take the context that the words in a sentence occur in into account in order to generate more representative embeddings (i.e., numeric representations of the text posts) <ref type="bibr">(Grootendorst, n.d-c;</ref><ref type="bibr">Yao et al., 2023)</ref>.</p><p>After preprocessing, the dataset contained 188,139 posts. The dates that the subreddit </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">Topic Modeling</head><p>The present work utilizes a NLP technique called topic modeling to extract the main topics of discussion within the kratom-related subreddit datasets. Specifically, we utilize BERTopic <ref type="bibr" target="#b19">(Grootendorst, 2022)</ref> for topic modeling as it was found to effectively generate interpretable topics in previous studies that analyzed unlabelled Reddit posts <ref type="bibr" target="#b4">(Choi &amp; Jang, 2023;</ref><ref type="bibr" target="#b51">Ng et al., 2023;</ref><ref type="bibr" target="#b54">Pleasants et al., 2023;</ref><ref type="bibr">Yao et al., 2023)</ref>.</p><p>BERTopic utilizes embeddings generated from Bidirectional Encoder Representations from Transformers (BERT) <ref type="bibr" target="#b10">(Devlin et al., 2018)</ref> and class-based term frequency-inverse document frequency (TF-IDF) to cluster posts into semantically similar topics <ref type="bibr" target="#b51">(Ng et al., 2023)</ref>. The BERT embeddings enable BERTopic to generate meaningful topic representations as context and meaning of words are taken into account <ref type="bibr" target="#b51">(Ng et al., 2023</ref><ref type="bibr" target="#b19">, Grootendorst, 2022)</ref>.</p><p>Class-based TF-IDF computes the significance of a word to a cluster of posts and calculates their frequency to generate the topics <ref type="bibr">(Yao et al., 2023)</ref>.</p><p>Python version 3.10.12 was used for data preprocessing and training BERTopic. A BERTopic model was trained using the BERTopic python library (version 0.16.0) <ref type="bibr" target="#b19">(Grootendorst, 2022</ref>). An overview of the hyperparameters set for the model have been included in Table <ref type="table" target="#tab_1">S1</ref> in the supplementary materials. While most of the default out-of-the-box values remained unchanged, we added a random state of 42 for the Uniform Manifold Approximation and Projection (UMAP) model to prevent stochastic behavior (i.e., producing different results each run) and therefore make the results reproducible. Lastly, additional stop words were filtered out during tokenisation to attempt to reduce noise being added to the topics (i.e., 'http', 'https', 'amp', 'com') <ref type="bibr">(Grootendorst, n.d-b)</ref>.</p><p>Subsequent to model training, the topics extracted by BERTopic are represented by a set of keywords and representative posts most relevant for a given topic. By default, these topics are labeled Topic 0 to N-1, where N is the number of topics generated minus 1. For clarity purposes, we modify the labeling to start from Topic 1, ending at Topic N. The keywords and samples of representative posts were provided to ChatGPT-4o using the following prompt template to create more descriptive topic labels for the top 10 topics <ref type="bibr">(Grootendorst, n.d.-a)</ref>:</p><p>"I have a topic that contains the following documents:</p><p>[DOCUMENTS]</p><p>The topic is described by the following keywords: <ref type="bibr">[KEYWORDS]</ref> Based on the information above, extract a short topic label in the following format:</p><p>topic: &lt;topic label&gt;"</p><p>Each topic label generated by ChatGPT-4o was also manually validated to ensure its appropriateness with respect to the representative keywords and documents. In addition, the representative posts within each cluster were visually inspected to support accurate interpretation and discussion of the topics.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.1">Dynamic Topic Modelling</head><p>Dynamic Topic Modelling (DTM) is a NLP technique used to outline the temporal evolution of the emergent topics within the time-stamped Reddit posts <ref type="bibr" target="#b2">(Blei &amp; Lafferty, 2006;</ref><ref type="bibr" target="#b19">Grootendorst, M., 2022;</ref><ref type="bibr" target="#b39">Jung et al., 2023)</ref>. Thus, it can provide us with insight into the trajectory of the increase or decline in discussions about specific topics over time <ref type="bibr" target="#b2">(Blei &amp; Lafferty, 2006)</ref>. We considered the entire timeframe of the dataset, spanning from September 2010 to December 2023. This range was selected because it captures the full historical evolution of discussions within the dataset, ensuring a comprehensive analysis of trends over time.</p><p>After training the BERTopic topic model (which does not consider any temporal component), a c-TF-IDF representation is computed for each topic and timestamp using BERTopic (version 0.16.0)'s topics_over_time module. The number of bins that are generated when computing the topic representations was set to 5 due to computational resource availability and to therefore increase the efficiency of the computations. To account for the growth in Reddit activity over the study period, topic prevalence was computed as the proportion of posts assigned to each topic within each time bin relative to the total number of posts in that bin. This normalization ensures that observed trends reflect changes in kratom-related discourse rather than overall increases in Reddit activity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">Results</head><p>To conduct an exploratory analysis on the topics that emerged between September 2010 and December 2023, we first look at the top 10 topic representations and their accompanying keywords that emerged from training the BERTopic model on the dataset (section 3.1). We subsequently conduct DTM to investigate the temporal variation in the frequency of discussions about these topics (section 3.2). Table <ref type="table" target="#tab_1">1</ref> provides an overview of the top 10 thematic topics that emerged, along with respective topic labels generated by ChatGPT-4o, top 10 representative words with the corresponding c-TF-IDF scores, and the number of posts per topic.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Main Topics of Discussion around Kratom</head><p>Subsection 3.1.1 will outline the top 10 topic representations for the present work's dataset in more detail.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.1">Topics that Emerged in the Dataset</head><p>BERTopic classified 130,235 posts out of the total 188,139 posts in the dataset as outliers and did not cluster them into particular topics. Initial results generated two similar topics related to kratom consumption in terms of dosage and tolerance within the top 10 most frequent topics. These two topics were therefore merged to improve interpretability. With the present hyperparameters, 524 topics were generated in total. An overview will only be provided about the top 10 most frequent topics that emerged as they represent the most frequently discussed themes from the analysis.</p><p>The most frequently discussed topic (Topic 1) centered on the theme of "Managing Kratom Tolerance and Dosage". This topic encompassed a total of 2,643 posts with specific terms shaping the conversation around the theme of kratom usage. The word 'tolerance' had the highest c-TF-IDF score (0.0123), indicating its central role in the conversations.</p><p>Similarly, terms like 'dose' (0.0074) and 'grams' (0.0063) were commonly used, reflecting users' concerns about the appropriate quantities for optimal consumption. Other keywords such as 'take' (0.0058) and 'break' (0.0053) point to common practices and strategies, such as taking specific dosages or initiating tolerance breaks. Additionally, the mention of everyday time frames like 'day' (0.0039) and 'per' (0.0037) suggests a collective interest in establishing routines and dosage schedules. As a whole, these keywords provide insight into a community interested in understanding and handling their kratom use through careful management of both dosage and tolerance.</p><p>The second most frequent topic was Topic 2, labeled "Kratom and Drug Testing: 'vendors' (0.0098), 'quality' (0.0094), and 'price' (0.0066). Overall, while Topic 3 was related to users' logistical concerns, Topic 4 was more so related to the selection and evaluation of vendors, with both topics contributing to the full picture of the kratom purchasing process.</p><p>Topics 5, 7, and 9 are all linked by their focus on kratom withdrawal and methods for managing withdrawal symptoms. However, each topic pertains to discussions addressing different approaches and substances.</p><p>Topic 5, which was labelled as 'Kratom Withdrawal and Gabapentin Use for Symptom Management', examines the use of 'gabapentin' (0.0231) for alleviating symptoms associated with kratom withdrawal. Discussions in this topic made specific references to dosage ('300mg'), and managing discomfort at different times of day ('day', 'night').</p><p>Moreover, conversations often mentioned 'withdrawal' (0.0027) and related terms like 'rls' (0.0034) and 'clonidine' (0.0029), reflecting the specific symptoms and medications involved in managing kratom withdrawal.</p><p>On the other hand, Topic 7 ("Suboxone and Kratom: Risks, Interactions, and Addiction Management"), shifts the focus to the interaction between 'suboxone' (0.0282) and kratom, as both substances are used for addiction management. Keywords such as 'withdrawals' (0.0038) and 'suboxone kratom' (0.0032) highlight conversations about its usage for managing kratom dependency or withdrawal. In a similar direction, discussions in Topic 9</p><p>("Kratom Tapering Strategies and Withdrawal Management") appeared to focus on strategies for gradually reducing kratom use. Terms like 'taper' (0.0141) and 'tapering' (0.0090) were central to the discussions, and keywords like 'doses' (0.0057), 'drop' (0.0039), and 'jump' (0.0054) indicate the conversations about the process of reducing doses at the end of the tapering process to minimize withdrawal symptoms. Taken together, topics 5, 7, and 9</p><p>highlight the various methods that users consider for managing kratom withdrawal, whether it is through the unsupervised use of medications like gabapentin or suboxone, or through gradual dose reduction strategies.</p><p>The sixth topic of discussion contained 1,031 posts related to potential challenges and concerns about traveling with kratom. It was therefore labeled as "Traveling with Kratom:</p><p>Legal Considerations and Packing Tips". The most common keywords related to the logistics of traveling with kratom, including concerns about airport security ( 'legal' (0.0160), 'bring' (0.0122), 'flying' (0.0226), and 'tsa' (0.0098)). Other commonly occurring keywords like 'luggage' (0.0113), 'bag' (0.0106), and 'checked' (0.0090) indicated users' discussions about how kratom should be packed and transported, and also sharing tips on carrying it safely through security checks.</p><p>Topic 8, labeled "Daily Encouragement and Well-being Updates", consisted of 905 posts focused on sharing personal experiences and offering support regarding mental and physical well-being during the process of quitting kratom. The most common keywords, such as 'today' (0.0082) and 'tomorrow' (0.0042), reflected users' daily reflections and their outlook for the future. Posts also frequently included words like 'better' (0.0057) and 'feeling' (0.0045), highlighting progress or struggles in personal well-being. Additionally, terms such as 'hope' (0.0041) and 'everyone' (0.0037) indicated a focus on maintaining a positive mindset and offering encouragement to others. Overall, this topic indicated that users would commonly provide a safe space for individuals to share their daily experiences, progress, and support for one another's well-being journeys.</p><p>Lastly, Topic 10 ("Methods and Recipes for Making Kratom Tea"), contained 783 posts centered around the preparation of kratom tea. Posts often included terms like 'tea' (0.0329), 'water' (0.0122) and 'boil' (0.0094), indicating the basic preparation steps, such as boiling water to make the tea. Ingredients such as 'lemon' (0.0103) and 'lemon juice' (0.0079)</p><p>were frequently mentioned, suggesting that users often add lemon to when brewing. Other keywords like 'filter' (0.0097), 'boiling' (0.0084), and 'powder' (0.0080) pointed to specific techniques for straining the tea or mixing the kratom powder. Overall, this topic focused on the different methods and recipes for preparing kratom tea, with users sharing tips and variations for making the process more enjoyable or effective.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">Dynamic Topic Modeling</head><p>Dynamic topic modeling was conducted to analyze how the frequency of the main topics of discussion that emerged from the Reddit posts varied over time <ref type="bibr" target="#b2">(Blei &amp; Lafferty, 2006;</ref><ref type="bibr" target="#b19">Grootendorst, 2022;</ref><ref type="bibr" target="#b39">Jung et al., 2023)</ref>. Figures <ref type="figure" target="#fig_5">2a</ref> and<ref type="figure" target="#fig_5">2b</ref> depict this temporal variation in the relative frequencies of the Top 10 topic representations for topics 1 to 5 and topics 6 -10, respectively.</p><p>For topics 1 to 5 that emerged from the dataset (Figure <ref type="figure" target="#fig_5">2A</ref>), Topic 4 ("Kratom Vendor For the remaining topics (Topics 6-10; Figure <ref type="figure" target="#fig_5">2B</ref>), Topic 6 ("Traveling with Kratom:</p><p>Legal Considerations and Packing Tips") was relatively stable across time, while Topic 10 ("Methods and Recipes for Making Kratom Tea") initially grew in frequency, peaking around 2013, before gradually declining. From around 2013 onward, Topics 7 ("Suboxone and Kratom: Risks, Interactions, and Addiction Management"), 8 ("Daily Encouragement and Well-being Updates"), and 9 ("Kratom Tapering Strategies and Withdrawal Management") steadily increased in prominence. By 2018, these three topics had overtaken Topics 6 and 10, and continued to increase or remain consistently higher in frequency of discussion through 2021.</p><p>Overall, we observe a decline in interest towards vendor reviews, products quality-price, and shipping/delivery issues. Conversely, we observe an increase in interest towards discussions related to kratom tolerance and dosage, management of withdrawal symptoms, tapering strategies, and peer support. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">Discussion</head><p>The present work utilized a NLP topic modeling approach (BERTopic) to identify common topics from and analyze the discourse made in kratom-related subreddits between September 2010 and December 2023. The analyzed dataset (n = 188,139) consisted of posts from 15 different subreddits processed from a public dataset containing data from the top 40,000 subreddits (Watchful1, n.d.). ChatGPT-4o was used to label the extracted topics based on the keywords and representative documents that emerged. The automatically generated labels were also manually validated to ensure appropriateness. In addition, the representative posts within each cluster were visually inspected to support accurate interpretation and discussion of the topics. DTM was also conducted to understand the temporal variation and evolution of the extracted topics from the dataset.</p><p>The results from the analysis of the dataset report a wide variety in the topics of discussion about kratom. The most discussed topic from 2016 onwards was about implementing effective strategies related to tolerance and dosage. Users shared posts on increased tolerance, dosage management, and also asked for advice on handling withdrawal symptoms experienced during tolerance break. Available research data suggest that a safe kratom dose is around 1.14-10.9 g in the US, which means 6.25-53.2 mg of mitragynine <ref type="bibr" target="#b36">(Huestis et al., 2024;</ref><ref type="bibr" target="#b56">Prevete et al., 2025;</ref><ref type="bibr" target="#b80">Smith et al., 2024;</ref><ref type="bibr">Tanna et al., 2022)</ref>. Moreover, regular users in the traditional context can consume several glasses of kratom per day, with different and higher mitragynine concentration <ref type="bibr">(Singh et al., 2019a,b,c)</ref>, but traditional preparations might be different from Western products <ref type="bibr">(Grundmann et al, 2024)</ref>. Existing studies show that kratom can cause withdrawal symptoms <ref type="bibr" target="#b87">(Stanciu et al., 2019)</ref>. These include both physical and psychological symptoms as described in regular users <ref type="bibr">(Singh et al., 2018a,b)</ref>, especially among prolonged high-dose kratom users and outside native countries <ref type="bibr" target="#b24">(Grundmann et al., 2023a)</ref>. To date, there is only limited clinical evidence on the pharmacological and toxicological profile of kratom and its alkaloids <ref type="bibr" target="#b36">(Huestis et al., 2024;</ref><ref type="bibr" target="#b56">Prevete et al., 2025;</ref><ref type="bibr" target="#b80">Smith et al., 2024;</ref><ref type="bibr">Tanna et al., 2022)</ref>. Thus, the findings highlight the need of more clinical trials for clarifying this aspect and facing challenges of kratom use outside of its traditional context, particularly in the absence of clear guidelines on safe dosage levels, on regulation on labelling of kratom products and potential interactions with other substances <ref type="bibr" target="#b23">(Grundmann et al., 2024b;</ref><ref type="bibr" target="#b32">Henningfield et al., 2024;</ref><ref type="bibr" target="#b63">Prozialeck et al., 2019)</ref>.</p><p>The second most commonly discussed topic on social media was about kratom and drug testing. Users would query about whether kratom usage shows on a urine or blood drug test. They would also ask how long kratom stays in one's body system. This highlights the growing concern around kratom detection, which aligns with the growing scientific effort in developing methods for accurate detection and assessment of kratom use <ref type="bibr" target="#b31">(Helander &amp; Rylski, 2023;</ref><ref type="bibr" target="#b70">Sempio et al., 2025)</ref>.</p><p>The third most common discussion topic that emerged from the dataset revolved around the challenges and complications that occur with the delivery process when receiving kratom in the mail. Users would describe their frustration, dissatisfaction, and issues with various postal services (predominantly United States and Canada based) losing, delaying, or not updating tracking information on kratom orders. Related to this is the fourth commonly discussed topic pertaining to reviewing vendors in the kratom market. In accordance with what was found by <ref type="bibr" target="#b65">Rogers et al., (2024a)</ref>, users would share experiences with various kratom sellers (e.g., with regards to reliability, customer service), and also discuss whether prices correlate with the quality of the kratom product. It is known that purity and safety concerns appear more prevalent in Western markets. This might be due to factors like the absence of a specific regulation, the risk of contaminants in kratom products which are not typically seen in traditional kratom <ref type="bibr" target="#b69">(Schwensohn et al., 2022;</ref><ref type="bibr" target="#b61">Prozialeck et al., 2022;</ref><ref type="bibr">2020)</ref>, or also higher mitragynine or 7-hydroxymitragynine concentrations <ref type="bibr" target="#b79">(Smith et al., 2025)</ref>, among other factors. These concerns highlight the potential risky diffusion of unregulated kratom products, including their availability on the dark web <ref type="bibr">(Prevete et al., 2023a)</ref>, which, like other new psychoactive substances, represent a challenge to traditional approaches to drug monitoring, surveillance, and control <ref type="bibr" target="#b43">(Kuypers et al., 2021)</ref>. Different ways to manage withdrawal symptoms when drug tapering was also frequently discussed in Topic 5, 7, 8, and 9. The central theme among the posts and keywords in the fifth most discussed topic captured users' experiences with utilizing Gabapentin, a medication commonly prescribed to alleviate withdrawal symptoms <ref type="bibr" target="#b97">(Vento et al., 2021;</ref><ref type="bibr">White, 2019)</ref>, but also associated with misuse <ref type="bibr" target="#b13">(Evoy et al., 2021)</ref>. In line with this, Reddit users in our study would express concerns with becoming dependent on Gabapentin and would seek out community support and advice.</p><p>Similarly, the seventh most discussed topic saw users discussing the use of Suboxone to manage addictions to kratom. While Suboxone is another drug often provided to treat opioid disorder <ref type="bibr" target="#b9">(Demick et al., 2020)</ref>, some representative posts from topic 7 showed that Reddit users would describe experiences with addiction transfer from kratom to Suboxone. These discussions likely reflect broader patterns of polysubstance self-management. In many cases, kratom does not represent users' first substance of dependence; individuals frequently report prior use of prescription opioids or benzodiazepines, and medications such as Gabapentin or Suboxone were likely introduced during earlier treatment attempts. Kratom is then adopted as a self-directed tapering tool (e.g., <ref type="bibr" target="#b53">Perry &amp; Chin, 2025;</ref><ref type="bibr" target="#b65">Rogers et al., 2024a;</ref><ref type="bibr" target="#b86">Smith et al., 2021)</ref>, giving rise to cyclical rather than linear transitions between substances. When users describe turning to Gabapentin or Suboxone to mitigate kratom withdrawal, these medications appear to be consumed without clinical supervision, often sourced from leftover prescriptions or informal channels, and accompanied by explicit worries about replacing one dependency with another. These practices should therefore not be understood as formal medical interventions for kratom cessation, but rather as lay adaptations of opioid withdrawal management strategies enacted in the absence of established clinical guidance. During the withdrawal process, users would also share their progress, express gratitude for community support, and provide words of encouragement to those also trying to stop their kratom usage (Topic 8). The ninth most discussed topic involved more broad discussions about desires and methods to quit kratom (e.g., including dosing schedules), withdrawal symptoms and coping strategies, as well as weighing the pros and cons of tapering versus quitting kratom cold-turkey. This finding supports earlier research <ref type="bibr" target="#b65">(Rogers et al., 2024a;</ref><ref type="bibr" target="#b86">Smith et al., 2021)</ref> that individuals may turn to platforms like Reddit for support from former kratom users when trying to reduce or quit use. Moreover, The DTM results showed that the frequency of discussions of Topic 5, 7, 8, and 9 have been increasing since 2016. The frequency in topics 5 and 7 (using Gabapentin and Suboxone, respectively) have mostly increased from 2016, there has been a continual increase in topic 8 ("Daily encouragement and well-being updates") and topic 9 ("Kratom tapering strategies and withdrawal management"). This continual increase is in line with the prevalence of topic 1 ("Managing Kratom Tolerance and Dosage), possibly suggesting an interest in kratom usage and management of kratom use disorder. This point highlights the need of further studies to better understand if kratom should be considered as a dangerous plant-based novel psychoactive substance or a potential plant based medicine, whose potential still needs to be fully understood.</p><p>In contrast to what was mentioned above, posts from topic 7 also discussed the use of kratom for substance use disorder recovery and maintenance. In this regard, some users reported considering using kratom to curb Suboxone addiction. These findings are in line with data from large surveys or studies, which have demonstrated that kratom is used without medical supervision in self-treating pain, psychiatric symptoms (e.g., depression and anxiety), dependence, and interrupting consumption of different substances, such as opioids, and methamphetamine <ref type="bibr" target="#b7">(Coe et al., 2019;</ref><ref type="bibr" target="#b17">Govarthnapany et al., 2025;</ref><ref type="bibr" target="#b27">Grundmann, 2017;</ref><ref type="bibr" target="#b59">Prevete et al. 2023b;</ref><ref type="bibr" target="#b67">Rogers et al., 2021;</ref><ref type="bibr" target="#b66">Rogers et al., 2024b;</ref><ref type="bibr" target="#b71">Singh et al., 2022)</ref>. Moreover, the use of kratom for substance use disorder recovery and maintenance aligns with the interest of the scientific community. Through in-vitro and animal models as well as pre-clinical studies, previous scientific work has found that kratom has potential in reducing alcohol intake <ref type="bibr" target="#b29">(Gutridge et al., 2020</ref><ref type="bibr" target="#b28">(Gutridge et al., , 2021))</ref>, opioid withdrawal and dependence <ref type="bibr" target="#b30">(Harun et al., 2020)</ref>, and diminishing alcohol withdrawal or seeking behavior <ref type="bibr" target="#b29">(Gutridge et al., 2020;</ref><ref type="bibr" target="#b99">Vijeepallam et al., 2019)</ref>. Additionally, a review by <ref type="bibr" target="#b47">Mukhopadhyay et al. (2023)</ref> has outlined the use of kratom and its alkaloids as potential pharmacotherapies for substance use disorder, pain, and opioid withdrawal. While related clinical work has been conducted (e.g., <ref type="bibr">Huestis et al., 2024;</ref><ref type="bibr">Tanna et al., 2022;</ref><ref type="bibr" target="#b98">Vicknasingam et al., 2020)</ref>, it is limited and leaves room for further investigation.</p><p>Another common topic of discussion related to the logistics of traveling with kratom for personal usage. Keywords and representative documents from Topic 6 showed that users were concerned with the legality of kratom in various states and countries as well as seeking advice on storing kratom in carry-on and checked luggage to avoid issues with airport security.</p><p>Lastly, methods to optimize brewing kratom as tea was the 10th most commonly discussed topic that emerged in the dataset. Kratom is traditionally and commonly consumed as tea <ref type="bibr" target="#b25">(Grundmann et al., 2023b)</ref>. Reddit users would provide instructions on how to prepare kratom tea as well as how to enhance its taste (e.g., using nutmeg, cinnamon, citrus juice) while still ensuring its potency.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">Limitations</head><p>There are a few limitations to the present study. First, the present investigation only considers a single social media platform (Reddit) and may further benefit from analyzing discussions from other forums or platforms. Additionally, although the majority of Reddit traffic comes from the United States, the absence of detailed user demographic information means that our findings should be interpreted as reflecting the experiences and perspectives of Reddit users rather than the general population. Secondly, only posts were considered for topic modeling analysis and not the accompanying comments. Further sub-discussions that may have occurred within the comments to a given post may have also revealed further insight into discussions about kratom on Reddit. Thirdly, a substantial number of posts (130,235 of 188,139) were classified as outliers and not assigned to topics due to the default hyperparameter settings, which ensures a conservative clustering approach. While adjusting hyperparameters may reduce the outlier rate, it may force posts into poorly defined clusters, compromising the reliability and interpretability of results <ref type="bibr">(Grootendorst, n.d.-c)</ref>.</p><p>Consequently, our insights primarily reflect the most thematically consistent discussions across 13 years, while less frequent or idiosyncratic conversations may not be captured and represented. Future research could explore alternative clustering strategies or parameter settings to better include these posts. For example, although regulatory debates surrounding the attempted Drug Enforcement Administration/Food and Drug Administration scheduling of kratom in 2016-2017 generated substantial public attention <ref type="bibr" target="#b53">(Perry &amp; Chin, 2025)</ref>, such discourse did not emerge as a distinct cluster in our BERTopic model, likely due to its brief temporal concentration and dispersion across mixed-context threads rather than forming a sustained, cohesive topic. Additionally, while the topic modeling procedure produced 524 clusters in total, only the most prevalent topics were manually inspected for coherence, as these accounted for the majority of the corpus and drove the key findings. Conducting an exhaustive manual validation of all clusters would offer limited additional value relative to its scale; however, we acknowledge that some infrequent or ambiguous topics may not be fully represented in our interpretation. Fourthly, the number of bins that were generated when computing the topic representations for dynamic topic modeling was set to 5 due to computational resource availability and to therefore increase the efficiency of the computations. Future research could explore using more bins to capture additional nuances in discussion content. Lastly, and as similarly addressed by <ref type="bibr" target="#b96">Valdez and Patterson (2022)</ref>, some caution must be applied towards drawing definitive insights from our analysis as the anonymity granted to Reddit users can put the authenticity of the posts into question. Further studies that include keywords related to kratom's main alkaloids (e.g., mitragynine, 7-hydroxymitragynine, speciogynine, paynantheine, corynantheidine) should be encouraged to enhance understanding of its use and impact.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2">Conclusion</head><p>The present work utilized BERTopic, a natural language processing topic modeling approach, to efficiently extract and analyze the main topics of discussion from a large corpora of Reddit posts made in kratom-related subreddits between September 2010 and December 2023 (n = 188,139). In general, the results of the study reveal and contextualize what individuals on Reddit think about kratom and how they communicate about it on a platform that allows them to fairly freely express themselves in an anonymous format. Various topics emerged including concerns about kratom and drug testing, recommendations for methods of consumption, and strategies to taper off kratom usage. The findings from our study, conducted on a larger scale, not only corroborate previous research but also strengthen their conclusions (e.g., <ref type="bibr" target="#b86">Smith et al., 2021;</ref><ref type="bibr" target="#b65">Rogers et al., 2024a)</ref>, revealing that users have reported both favorable and unfavorable experiences with kratom usage. Additionally, the DTM analysis furthermore suggests a declining interest towards vendor reviews, products quality-price, and shipping/delivery issues and a growing trend in discussions about negative experiences with kratom, which encourages individuals to use other substances (e.g., Gabapentin, Suboxone) without medical supervision in order to mitigate kratom withdrawal symptoms, taper off, or quit using it. Overall, the findings demonstrate the potential of social media discussions for informing healthcare professionals, policymakers, and researchers about users' attitudes and experiences with kratom, thereby guiding interventions, policies, and further scientific studies and supporting future clinical trials, which are necessary for generating a more balanced perception on kratom safety and risks.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>posts were made spanned from September 2010 to December 2023. The number of posts per subreddit was as follows: r/addiction (n = 651 posts), r/chronicpain (n = 654 posts), r/opiatesrecovery (n = 3323 posts), r/kratom (n = 95,572 posts), r/kratomm (n = 2330 posts), r/recreationalkratom (n = 1660 posts), r/smallbatchkratom (n = 1787 posts), r/vendorsofkratom (n = 5,483 posts), r/vendorsofkratom2 (n = 1099 posts), r/quittingkratom (n = 64,935 posts), r/kratomkorner (n = 5486 posts), r/Kratom_Info_Exchange (n = 1360 posts), r/KratomGarden (n = 975 posts), r/kratomreview100 (n = 1258 posts), and r/kratomreview101 (n = 1566 posts).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1</head><label>1</label><figDesc>Figure 1 visualizes the top 10 topics and the top 5 words with the highest class TF-IDF scores</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>False</head><label></label><figDesc>Positives and Detection", and was discussed in 1,140 posts. The key terms included 'test' (0.0355), 'drug test' (0.0193), and 'drug' (0.0169), reflecting conversations surrounding concerns about how kratom may affect drug testing results. Discussions also frequently mentioned 'false' (0.0128), 'false positive' (0.0102), and 'tested' (0.0123), emphasizing worries about inaccurate results. Topic 3 ("Kratom Shipping and Delivery Issues") and Topic 4 ("Kratom Vendor Reviews and Price vs. Quality Debate"), are closely linked as they both focus on the broader kratom purchasing experience. While Topic 3 centers on concerns about the shipping process, such as tracking, delivery times, and postal services, Topic 4 shifts the focus to the vendors themselves, highlighting the quality and pricing of kratom. For instance, the most frequent keywords in Topic 3 included 'tracking' (0.0160), 'USPS' (0.0152), and 'package' (0.0145), highlighting concerns about tracking shipments and using postal services. Conversely, Topic 4's most representative keywords related to kratom sellers and their quality, including</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 1 :</head><label>1</label><figDesc>Figure 1: Top 5 representative words based on class-based term frequency-inverse document</figDesc><graphic coords="17,73.50,72.37,451.50,303.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc>Reviews and Price vs. Quality Debate") was the most frequently discussed topic before 2014, reaching its peak around 2013. However, its relative frequency dropped sharply after 2013, reaching its lowest in 2018. Topic 3 ("Kratom Shipping and Delivery Issues") also peaked in 2013, but subsequently declined in parallel with Topic 4 in the following years. In contrast, Topic 1 ("Managing Kratom Tolerance and Dosage") became the dominant topic of discussion after 2016 and maintained higher relative frequency through 2021. Topic 2 ("Kratom and Drug Testing: False Positives and Detection") remained relatively stable over time, with gradual increases but consistently below other topics. Topic 5 ("Kratom Withdrawal and Gabapentin Use for Symptom Management") started being discussed around 2013, with its frequency rising after 2016 and surpassing Topics 2, 3, and 4 after 2018.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 2 :</head><label>2</label><figDesc>Figure 2: Temporal variations in the relative frequencies of (A) topics 1 -5 and (B) topics 6 -</figDesc><graphic coords="21,73.50,320.75,498.75,166.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 :</head><label>1</label><figDesc>Top 10 thematic topics that emerged with respective topic labels, top 10 keywords, and number of posts for the dataset consisting of 15 subreddits (r/addiction, r/chronicpain,</figDesc><table><row><cell>Topic number</cell><cell>Topic</cell><cell>label</cell><cell>Representative</cell><cell>words</cell><cell>Number</cell><cell>of</cell></row><row><cell></cell><cell>generated</cell><cell>by</cell><cell>(c-TF-IDF score)</cell><cell></cell><cell cols="2">representativ</cell></row></table></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Materials</head><p>Table <ref type="table">S1</ref>: Hyperparameters set for each module of BERTopic, including a brief description of the purpose of each module. Most default values are retained from instantiating BERTopic out-of-the-box..  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethical Approval</head><p>This study was approved by the University of Trento Ethical Committee (2024-40 ESA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>References</head><p>White, C. M. ( <ref type="formula">2019</ref>). Pharmacologic and clinical assessment of kratom: An update. American Journal of <ref type="bibr">Health-System Pharmacy, 76(23), 1915</ref><ref type="bibr">-1925</ref><ref type="bibr">. White, C. M., Belcourt, J., &amp; Sedensky, A. (2025)</ref> </p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Kratom from head to toe-case reviews of adverse events and toxicities</title>
		<author>
			<persName><forename type="first">E</forename><surname>Alsarraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Myers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Culbreth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fanikos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current Emergency and Hospital Medicine Reports</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="141" to="168" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The pushshift reddit dataset</title>
		<author>
			<persName><forename type="first">J</forename><surname>Baumgartner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zannettou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Keegan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Squire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Blackburn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proceedings of the international AAAI conference on web and social media</title>
		<meeting>the international AAAI conference on web and social media</meeting>
		<imprint>
			<date type="published" when="2020-05">2020, May</date>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="830" to="839" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Dynamic topic models</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Blei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Lafferty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proceedings of the 23rd international conference on Machine learning</title>
		<meeting>the 23rd international conference on Machine learning</meeting>
		<imprint>
			<date type="published" when="2006-06">2006. June</date>
			<biblScope unit="page" from="113" to="120" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: Implications for products sold as kratom</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Murch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Ethnopharmacology</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="302" to="325" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Topic and Sentiment Analysis of Reddit&apos;s Vaping-Cessation Community</title>
		<author>
			<persName><forename type="first">J</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">2023 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)</title>
		<imprint>
			<publisher>IEEE</publisher>
			<date type="published" when="2023">2023</date>
			<biblScope unit="page" from="4878" to="4880" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">E</forename><surname>Cinosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Martinotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Simonato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Demetrovics</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roman-Urrestarazu</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Following &quot;the roots&quot; of Kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in western countries</title>
		<author>
			<persName><forename type="first">O</forename><surname>Corazza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BioMed research international</title>
		<imprint>
			<biblScope unit="volume">2015</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">968786</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Kratom as a substitute for opioids: results from an online survey</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Coe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pillitteri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sembower</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Gerlach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Henningfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and alcohol dependence</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="24" to="32" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Characteristics of deaths associated with kratom use</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Corkery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Streete</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Claridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Goodair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Papanti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Orsolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Hendricks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1102" to="1123" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Kratom: a growing substance of abuse in the United States</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Demick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Summers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>El-Mallakh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annals of Clinical Psychiatry</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="8" to="13" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Bert: Pre-training of deep bidirectional transformers for language understanding</title>
		<author>
			<persName><forename type="first">J</forename><surname>Devlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Toutanova</surname></persName>
		</author>
		<idno type="arXiv">arXiv:1810.04805</idno>
		<imprint>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="report_type">arXiv preprint</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Evaluating the drug interactions in kratom Usage: clinical application</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Dhoble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Mccurdy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opinion on Drug Metabolism &amp; Toxicology</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="949" to="959" />
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A topic modeling comparison between lda, nmf, top2vec, and bertopic to demystify twitter posts</title>
		<author>
			<persName><forename type="first">R</forename><surname>Egger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in sociology</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">886498</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Abuse and misuse of pregabalin and gabapentin: a systematic review update</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Evoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sadrameli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Covvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Peckham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Morrison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="125" to="156" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Polysubstance use profiles among US adults using Kratom (Mitragyna speciosa): A latent class analysis using The National Survey on Drug Use and Health (NSDUH)</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Falise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Hoeflich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Nutley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lopez-Quintero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Striley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The American journal on addictions</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="76" to="80" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Fong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Carollo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vivanti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Messinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dimitriou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Esposito</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Autism Spectrum Disorders Discourse on Social Media Platforms: A Topic Modeling Study of Reddit Posts</title>
	</analytic>
	<monogr>
		<title level="j">Autism research</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Ozempic (Glucagon-like peptide 1 receptor agonist) in social media posts: unveiling user perspectives through Reddit topic modeling</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Carollo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lazuras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Corazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Esposito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Govarthnapany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gabrhelik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Emerging Trends in Drugs, Addictions, and Health, 4, 100157</title>
		<imprint>
			<date type="published" when="2024">2024. 2025</date>
			<biblScope unit="page" from="1" to="11" />
		</imprint>
	</monogr>
	<note>Kratom (Mitragyna speciosa Korth.) Use Among Poly-Drug Users in Southeast Asia: A Systematic Review</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Kratom as a potential substance use disorder harm reduction agent</title>
		<author>
			<persName><forename type="first">M</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Vadiei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Veltri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Evoy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Public Health</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">1416689</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">BERTopic: Neural topic modeling with a class-based TF-IDF procedure</title>
		<author>
			<persName><forename type="first">M</forename><surname>Grootendorst</surname></persName>
		</author>
		<idno type="arXiv">arXiv:2203.05794</idno>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="report_type">arXiv preprint</note>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Grootendorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Llm &amp; Generative</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ai -Bertopic</forename></persName>
		</author>
		<ptr target="https://maartengr.github.io/BERTopic/getting_started/best_practices/best_practices.html" />
		<imprint>
			<date type="published" when="2024-03">March 2024. March 2024</date>
		</imprint>
	</monogr>
	<note type="report_type">M. P. (n.d.-b). Best Practices -BERTopic</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">FAQ -BERTopic</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Grootendorst</surname></persName>
		</author>
		<ptr target="https://maartengr.github.io/BERTopic/faq.html#how-do-i-remove-stop-words" />
		<imprint>
			<date type="published" when="2024-03">March 2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Prozialeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Veltri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Boyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Commentary: Presence of kratom in opioid overdose deaths: findings from coroner postmortem toxicological report</title>
		<imprint>
			<date type="published" when="2024">2024a</date>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">1411964</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Not all kratom is equal: The important distinction between native leaf and extract products</title>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Garcia-Romeu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Mccurdy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Swogger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Weiss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addiction</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="202" to="203" />
			<date type="published" when="2024">2024b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Hendrickson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Greenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Kratom: history, pharmacology, current user trends, adverse health effects and potential benefits</title>
		<imprint>
			<date type="published" when="2023">2023a</date>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page">101442</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Correlations of kratom (Mitragyna speciosa Korth.) tea bag preparations and reported pharmacological effects</title>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Al Barzanji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Hazrat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kaur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Negeve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Veltri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Ethnopharmacology</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="page">116779</biblScope>
			<date type="published" when="2023">2023b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">How essential is kratom availability and use during COVID-19? Use pattern analysis based on survey and social media data</title>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Veltri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Morcos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Iii</forename><surname>Knightes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Substance Abuse</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="865" to="877" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Patterns of kratom use and health impact in the US-results from an online survey</title>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and alcohol dependence</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="63" to="70" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Evaluation of kratom opioid derivatives as potential treatment option for alcohol use disorder</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Gutridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chakraborty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Varga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Majumdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Van Rijn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Pharmacology</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">764885</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Gutridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Robins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Cassell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Uprety</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Mores</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Van Rijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">British journal of pharmacology</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1497" to="1513" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats</title>
		<author>
			<persName><forename type="first">N</forename><surname>Harun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Johari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Mansor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shoaib</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">237</biblScope>
			<biblScope unit="page" from="855" to="867" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Drug testing for mitragynine and kratom: Analytical challenges and medico-legal considerations</title>
		<author>
			<persName><forename type="first">A</forename><surname>Helander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rylski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Testing and Analysis</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="213" to="219" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Kratom safety and toxicology in the public health context: research needs to better inform regulation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Henningfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Huestis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Pharmacology</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">1403140</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and Alcohol Dependence</title>
		<imprint>
			<biblScope unit="volume">272</biblScope>
			<biblScope unit="page">112701</biblScope>
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Prevalence of kratom use disorder among kratom consumers</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Stanciu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Addiction Medicine</title>
		<imprint>
			<biblScope unit="page" from="10" to="1097" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">A drug toxicity death involving propylhexedrine and mitragynine</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Holler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Vorce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Mcdonough-Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Magluilo</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Solomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Levine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of analytical toxicology</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="54" to="59" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Human mitragynine and 7-hydroxymitragynine pharmacokinetics after single and multiple daily doses of oral encapsulated dried kratom leaf powder</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Huestis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Brett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bothmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Atallah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecules</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">984</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Examining the psychoactive differences between kratom strains</title>
		<author>
			<persName><forename type="first">G</forename><surname>Huisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Menke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schreiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mason</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International journal of environmental research and public health</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page">6425</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">A Kratomic Bomb: Cardiotoxicities From Mitragyna speciosa Extract</title>
		<author>
			<persName><forename type="first">V</forename><surname>Jain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lloyd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Case Reports</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">103110</biblScope>
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Unveiling Cryptocurrency Conversations: Insights From Data Mining and Unsupervised Learning Across Multiple Platforms</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">IEEE Access</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="130573" to="130583" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kamble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">I</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Berthold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>LeÃ³n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K L</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Avery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Toxicology letters</title>
		<imprint>
			<biblScope unit="volume">319</biblScope>
			<biblScope unit="page" from="148" to="154" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Kratom: A systematic review of toxicological issues</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kerrigan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Basiliere</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Wiley Interdisciplinary Reviews: Forensic Science</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">1420</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Kruegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="108" to="120" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Emerging Trends in Novel Psychoactive Substances and Health Consequences. Emerging Trends in Drugs</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P C</forename><surname>Kuypers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Bersani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Vicknasingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roman-Urrestarazu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Corazza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addictions, and Health</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="10" to="1016" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">Uncovering Concerns of Citizens Through Machine Learning and Social Network Sentiment Analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kumi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Snow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Lomotey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Deters</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2024">2024</date>
			<publisher>IEEE Access</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The adverse cardiovascular effects and cardiotoxicity of kratom (Mitragyna speciosa Korth.): a comprehensive review</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F I</forename><surname>Leong Bin Abdullah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Pharmacology</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">726003</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Mccurdy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Veltri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Review of Clinical Pharmacology</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="131" to="142" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Receptor selectivity and therapeutic potential of kratom in substance use disorders</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mukhopadhyay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wilkerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Mcmahon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Mccurdy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current Addiction Reports</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="304" to="316" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Kratom-From natural remedy to addictive drug and back</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>MÃ¼ller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>MÃ¼ller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Der Nervenarzt</title>
		<imprint>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Kratom (Mitragyna speciosa) use for self-management of pain: Insights from cross-sectional and ecological momentary assessment data</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Mun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Panlilio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thrul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Mccurdy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of Pain</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page">104726</biblScope>
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Kratom adulterated with phenylethylamine and associated intracerebral hemorrhage: linking toxicologists and public health officials to identify dangerous adulterants</title>
		<author>
			<persName><forename type="first">N</forename><surname>Nacca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schult</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Spink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ginsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Navarette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Marraffa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of medical toxicology</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="71" to="74" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Examining the Public Messaging on &apos;Loneliness&apos; over Social Media: An Unsupervised Machine Learning Analysis of Twitter Posts over the Past Decade</title>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">X</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y X</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Yau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">X</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Liew</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Healthcare</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">1485</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Forensic implications of kratom: kratom toxicity, correlation with mitragynine concentrations, and polypharmacy</title>
		<author>
			<persName><forename type="first">D</forename><surname>Papsun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brower</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Logan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current Addiction Reports</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="272" to="281" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Kratom drinks and consumption trends: insights from Reddit</title>
		<author>
			<persName><forename type="first">T</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Substance Use</title>
		<imprint>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">UNDERSTANDING R/ABORTION THROUGH NATURAL LANGUAGE PROCESSING: USING A DYNAMIC TOPIC MODELING APPROACH TO EXPLORE USE OF AN ONLINE COMMUNITY FOR ABORTION DURING 2022</title>
		<author>
			<persName><forename type="first">E</forename><surname>Pleasants</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weidert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">D</forename><surname>Upadhyay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cheshire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Contraception</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page">110187</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Kava (Piper methysticum) in the United States: the quiet rise of a substance with often subtle effects</title>
		<author>
			<persName><forename type="first">S</forename><surname>Pont-Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kheyfets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The American Journal of Drug and Alcohol Abuse</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="85" to="96" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans</title>
		<author>
			<persName><forename type="first">E</forename><surname>Prevete</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Theunissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Kuypers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Paci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Reckweg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cavarra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Ramaekers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">242</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1363" to="1376" />
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">E</forename><surname>Prevete</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Catalani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Kuypers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Theunissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Townshend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">A Preliminary Inventory of Kratom (Mitragyna Speciosa) Products and Vendors on the Darknet and Cryptomarkets</title>
		<author>
			<persName><forename type="first">O</forename><surname>Corazza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Psychoactive Drugs</title>
		<imprint>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Clinical implications of Kratom (Mitragyna speciosa) use: a literature review</title>
		<author>
			<persName><forename type="first">E</forename><surname>Prevete</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P C</forename><surname>Kuypers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Theunissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Esposito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Ramaekers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pasquini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Corazza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current Addiction Reports</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="317" to="334" />
			<date type="published" when="2023">2023b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Exploring the use of Kratom (Mitragyna speciosa) via the YouTube data tool: A novel netnographic analysis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Prevete</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hupli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Marrinan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>D'udine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bersani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Corazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Emerging trends in drugs, addictions, and health</title>
		<imprint>
			<date type="published" when="2021">2021</date>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">100007</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Public health implications and possible sources of lead (Pb) as a contaminant of poorly regulated kratom products in the United States</title>
		<author>
			<persName><forename type="first">W</forename><surname>Prozialeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Edwards</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Toxics</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">398</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Evaluation of the mitragynine content, levels of toxic metals and the presence of microbes in kratom products purchased in the western suburbs of Chicago</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Prozialeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Lamar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Plotkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Sigar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Veltri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Environmental Research and Public Health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page">5512</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Kratom policy: the challenge of balancing therapeutic potential with public safety</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Prozialeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Avery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Henningfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Kruegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Drug Policy</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="70" to="77" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">The effects of kratom (Mitragyna speciosa) on metabolic syndrome-related parameters: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rayanakorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Apisitwittaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yaja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Inpan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Na Takuathung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Koonrungsesomboon</surname></persName>
		</author>
		<ptr target="https://www.redditinc.com/" />
	</analytic>
	<monogr>
		<title level="j">Frontiers in Pharmacology</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">1587528</biblScope>
			<date type="published" when="2024-02-01">2025. 2024, February 1</date>
		</imprint>
	</monogr>
	<note>Reddit Homepage</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Growing pains with kratom: experiences discussed in subreddits contrast with satisfaction expressed in surveys</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Colvin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Mccurdy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Pharmacology</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">1412397</biblScope>
			<date type="published" when="2024">2024a</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: Insights from dosing amount versus frequency</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and Alcohol Dependence</title>
		<imprint>
			<biblScope unit="volume">260</biblScope>
			<biblScope unit="page">111329</biblScope>
			<date type="published" when="2024">2024b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Kratom use in the US: both a regional phenomenon and a white middle-class phenomenon? Evidence from NSDUH 2019 and an online convenience sample</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Strickland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Pharmacology</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">789075</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Kratom (Mitragyna Speciosa) liver injury: a comprehensive review</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schimmel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Dart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="263" to="283" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">A multiple-serotype outbreak of Salmonella infections linked to Kratom</title>
		<author>
			<persName><forename type="first">C</forename><surname>Schwensohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nsubuga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cronquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Jose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mastel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mccullough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Gieraltowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Foodborne Pathogens and Disease</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="648" to="653" />
			<date type="published" when="2017">2022. 2017-2018</date>
			<pubPlace>United States</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Quantification of 11 kratom alkaloids including mitragynine and its main metabolites in human plasma using LC-MS/MS</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sempio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Campos-Palomino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Klawitter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Huestis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Christians</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Klawitter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Analytical and Bioanalytical Chemistry</title>
		<imprint>
			<biblScope unit="volume">417</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="761" to="769" />
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Effects of kratom (Mitragyna speciosa Korth.) in reducing risk-behaviors among a small sample of HIV positive opiate users in Malaysia</title>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Narayanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F I L</forename><surname>Abdullah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vicknasingam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of ethnicity in substance abuse</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1285" to="1295" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Constipation prevalence and fatigue severity in regular kratom (Mitragyna speciosa Korth.) users</title>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Damodaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Prozialeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Karunakaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vicknasingam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Substance Use</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="233" to="239" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Effects of kratom (mitragyna speciosa korth.) use in regular users</title>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Narayanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Dzulkapli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vicknasingam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Substance Use &amp; Misuse</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="2284" to="2289" />
			<date type="published" when="2019">2019b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Long-term cognitive effects of Kratom (Mitragyna speciosa Korth.) use</title>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Narayanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>MÃ¼ller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vicknasingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>YÃ¼cel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T W</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Mansor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of psychoactive drugs</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="19" to="27" />
			<date type="published" when="2019">2019c</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Severity of kratom (Mitragyna speciosa Korth.) psychological withdrawal symptoms</title>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Narayanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>MÃ¼ller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Swogger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Rahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F I</forename><surname>Leong Bin Abdullah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Vicknasingam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of psychoactive drugs</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="445" to="450" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note>a)</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Severity of pain and sleep problems during kratom (Mitragyna speciosa Korth.) cessation among regular kratom users</title>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><surname>Narayanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Vicknasingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Prozialeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ramanathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zainal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Harun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Psychoactive Drugs</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="266" to="274" />
			<date type="published" when="2018">2018b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Narayanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vicknasingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Corazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Santacroce</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Roman-Urrestarazu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Human Psychopharmacology: Clinical and Experimental</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">2582</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">The rise of novel, semi-synthetic 7-hydroxymitragynine products</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Mccurdy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addiction</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="387" to="388" />
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Responses to a &quot;typical&quot; morning dose of kratom in people who use kratom regularly: a direct-observation study</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Mccurdy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Epstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of addiction medicine</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="144" to="152" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Kratom&apos;s emergence and persistence within the US polydrug epidemic</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Feldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current addiction reports</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="262" to="271" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Mccurdy</surname></persName>
		</author>
		<author>
			<persName><surname>Garcia-Romeu</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">,</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Kratom use as more than a &quot;self-treatment</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The American journal of drug and alcohol abuse</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="684" to="694" />
			<date type="published" when="2022">2022a</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Social, psychological, and substance use characteristics of US adults who use kratom: Initial findings from an online, crowdsourced study</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Garcia-Romeu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Swogger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Epstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Experimental and clinical psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">983</biblScope>
			<date type="published" when="2022">2022b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schriefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug and Alcohol Dependence</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="page">108879</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Kratom withdrawal: a systematic review with case series</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Stanciu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Gnanasegaram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Penders</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of psychoactive drugs</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="12" to="18" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Understanding kratom use: a guide for healthcare providers</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Swogger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Garcia-Romeu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Veltri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Henningfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Y</forename><surname>Busch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in pharmacology</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">801855</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Experiences of kratom users: a qualitative analysis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Swogger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Erowid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Erowid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Trabold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">.</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of psychoactive Drugs</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="360" to="367" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Translating kratom-drug interactions: from bedside to bench and back</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Tanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Cech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Oberlies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Rettie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Thummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Paine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Metabolism and Disposition</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="923" to="935" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Tanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Hadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Manwill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Flores-Bocanegra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Layton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Clinical pharmacokinetic assessment of kratom (Mitragyna speciosa), a botanical product with opioid-like effects, in healthy adult participants</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Paine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmaceutics</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">620</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tobacyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Parks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lovelady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Brents</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Drug Policy</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page">103817</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<author>
			<persName><forename type="first">T</forename><surname>Torrico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nikolov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Salam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Padhy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Weinstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Presence of kratom in opioid overdose deaths: findings from coroner postmortem toxicological report</title>
		<imprint>
			<date type="published" when="2024">2024</date>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1332999</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<author>
			<persName><forename type="first">N</forename><surname>Vadiei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Evoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Grundmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">The Impact of Diverse Kratom Products on Use Patterns, Dependence, and Toxicity</title>
		<imprint>
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Computational analyses identify addiction help-seeking behaviors on the social networking website Reddit: Insights into online social interactions and addiction support communities</title>
		<author>
			<persName><forename type="first">D</forename><surname>Valdez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Patterson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLOS Digital Health</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">143</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Case report: treatment of kratom use disorder with a classical tricyclic antidepressant</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Vento</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>De Persis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>De Filippis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schifano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Napoletano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Corkery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Kotzalidis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in psychiatry</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">640218</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Kratom and Pain Tolerance: A Randomized, Placebo-Controlled, Double-Blind Study</title>
		<author>
			<persName><forename type="first">B</forename><surname>Vicknasingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Chooi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Rahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ramachandram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ramanathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S M</forename><surname>Yusof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zainal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Murugaiyah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gueorguieva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Mansor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Chawarski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Yale journal of biology and medicine</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="229" to="238" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Methanolic extract of Mitragyna speciosa Korth leaf inhibits ethanol seeking behaviour in mice: Involvement of antidopaminergic mechanism</title>
		<author>
			<persName><forename type="first">K</forename><surname>Vijeepallam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pandy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Murugan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Naidu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Metabolic brain disease</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1713" to="1722" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Health benefits and adverse effects of kratom: A social media text-mining approach</title>
		<author>
			<persName><forename type="first">A</forename><surname>Wahbeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Al-Ramahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>El-Gayar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nasralah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Elnoshokaty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Informatics</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">63</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Reddit language indicates changes associated with diet, physical activity, substance use, and smoking during COVID-19</title>
		<author>
			<persName><forename type="first">K</forename><surname>Wanchoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abrams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Merchant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ungar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Guntuku</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Plos one</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">280337</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Subreddit comments/submissions 2005-06 to 2023-12</title>
		<ptr target="https://www.reddit.com/r/pushshift/comments/1akrhg3/separate_dump_files_for_the_top_40k_subreddits/" />
	</analytic>
	<monogr>
		<title level="j">Watchful</title>
		<imprint>
			<date type="published" when="2024-02">February 2024</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
